![]() ![]() Investors can start off the day with a breakdown of the. The 1 analysts offering 12-month price forecasts for Tyme Technologies Inc have a median target of 8.00, with a high estimate of 8.00 and. operates as a subsidiary of Syros Pharmaceuticals, Inc. (TYME) stock quote, history, news and other vital information to help you with your stock trading and investing. Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. As of September 16, 2022, Tyme Technologies, Inc. Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology. The Stock rose vividly during the last session to 0.2997 after opening rate of 0.26 while the lowest price it went was recorded 0.26 before closing at 0.26. (TYME), which is 0.29 to be very precise. 98362 PH : 206 / 457 - 9087 OLD TYME GOGGLES 27 including shipping. ![]() The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. Let’s start up with the current stock price of Tyme Technologies Inc. WANTED : 1962 - 1967 SPORTSTER XLCH in immaculate, 100 stock condition with. The company was formerly known as Global Group Enterprises Corp. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. How much money does Tyme Technologies make Tyme Technologies (NASDAQ:TYME) has a. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. One share of TYME stock can currently be purchased for approximately 0.26. Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |